Lowenstein represented First Wave BioPharma, Inc. in the transaction.First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
